Availability and Appropriateness of Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia in 10 Countries

Authors:
  • MCMarcia G. Crosse
    Marcia G. Crosse
  • EPEric A. Peterson
    Eric A. Peterson
  • RWRichard C. Weston
    Richard C. Weston
  • MHMary M. Horowitz
    Mary M. Horowitz
  • FAFrederick R. Appelbaum
    Frederick R. Appelbaum
  • BCBruce D. Cheson
    Bruce D. Cheson

Abstract
Allogeneic bone marrow transplantation, a sophisticated and expensive procedure, is the only curative therapy for chronic myeloid leukemia (CML). We examined the availability and appropriateness of allogeneic bone marrow transplantation for CML in 10 economically advanced countries with diverse health care systems. For each country we obtained data on the likelihood of transplantation to treat CML in patients under the age of 55 years, the length of time from diagnosis to transplantation, and the stage of disease at the time of transplantation.

This publication has 14 references indexed in Scilit: